Get the Stockscreener App
4.80
2.56%
0.12
After Hours:
4.80
Immucell Corp stock is traded at $4.80, with a volume of 24,448.
It is up +2.56% in the last 24 hours and down -21.05% over the past month.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
See More
Previous Close:
$4.68
Open:
$4.75
24h Volume:
24,448
Relative Volume:
1.43
Market Cap:
$43.42M
Revenue:
$23.84M
Net Income/Loss:
$-3.81M
P/E Ratio:
-9.60
EPS:
-0.5
Net Cash Flow:
$-713.00K
1W Performance:
+1.27%
1M Performance:
-21.05%
6M Performance:
-26.38%
1Y Performance:
+29.73%
1-Day Range:
$4.72
$5.36
1-Week Range:
$4.52
$5.36
52-Week Range:
$3.55
$7.60
Immucell Corp Stock (ICCC) Company Profile
Name
Immucell Corp
Sector
Industry
Phone
(207) 878-2770
Address
56 EVERGREEN DR, PORTLAND, ME
Compare ICCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCC
Immucell Corp
|
4.80 | 42.33M | 23.84M | -3.81M | -713.00K | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immucell Corp Stock (ICCC) Latest News
ImmuCell Corp (ICCC) Q3 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... By GuruFocus - Investing.com Canada
Will ImmuCell Corporation stock sustain high P E ratiosM&A Rumor & Safe Investment Capital Preservation Plans - newser.com
ICCC Stock Down Despite Y/Y Q3 Earnings Improvement & Margin Strength - Yahoo Finance
Why ImmuCell Corporation stock is a must watch in 2025Trade Risk Report & Daily Profit Maximizing Tips - newser.com
Will ImmuCell Corporation (IUL) stock benefit from sector leadershipJuly 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Will ImmuCell Corporation bounce back from current supportJuly 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com
How to monitor ImmuCell Corporation with trend dashboards2025 Investor Takeaways & Safe Capital Growth Stock Tips - newser.com
ImmuCell Corporation (NASDAQ:ICCC) Q3 2025 Earnings Call Transcript - Insider Monkey
ImmuCell Corp. Experiences Valuation Adjustment Amidst Strong Yearly Performance Metrics - Markets Mojo
What catalysts could drive ImmuCell Corporation stock higherWeekly Risk Report & Community Consensus Trade Signals - newser.com
Earnings call transcript: ImmuCell Q3 2025 sees stock dip amid revenue fall - Investing.com Canada
ImmuCell Q3 2025 slides: Improved margins despite revenue dip, Re-Tain awaits FDA - Investing.com
How ImmuCell Corporation (IUL) stock valuation compares with sectorJuly 2025 Trends & Long-Term Growth Stock Strategies - Fundação Cultural do Pará
ImmuCell Corporation Reports Third Quarter 2025 Financial Results with Significant Year-Over-Year Improvements in Net Income and Gross Margin - Quiver Quantitative
[8-K] IMMUCELL CORP /DE/ Reports Material Event | ICCC SEC FilingForm 8-K - Stock Titan
ImmuCell (NASDAQ: ICCC) posts $1.8M net income for nine months; gross margin at 42.6% - Stock Titan
Financial Review: CompuMed (OTCMKTS:CMPD) vs. ImmuCell (NASDAQ:ICCC) - Defense World
Multi asset correlation models including ImmuCell CorporationJuly 2025 Sentiment & Fast Exit Strategy with Risk Control - newser.com
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025 - The Manila Times
ImmuCell (NASDAQ: ICCC) schedules third-quarter results for Nov 13; call Nov 14 - Stock Titan
Why ImmuCell Corporation stock is seen as undervaluedWeekly Earnings Recap & Verified Short-Term Plans - newser.com
What MACD signals say about ImmuCell CorporationJuly 2025 Selloffs & Verified Entry Point Detection - newser.com
ImmuCell appoints Olivier te Boekhorst as new CEO - Investing.com
ImmuCell appoints Olivier te Boekhorst as new CEO By Investing.com - Investing.com Canada
ImmuCell Corporation Announces Appointment of New CEO Olivier te Boekhorst and Board Changes - Quiver Quantitative
ImmuCell (NASDAQ: ICCC) names Olivier te Boekhorst CEO, effective Nov 1, 2025 - Stock Titan
ImmuCell (NASDAQ:ICCC) Stock Passes Above 200 Day Moving AverageHere's What Happened - MarketBeat
Will ImmuCell Corporation stock rally after Fed decisionsProfit Target & Fast Gain Swing Trade Alerts - newser.com
Is ImmuCell Corporation stock positioned for long term growthSwing Trade & Reliable Intraday Trade Plans - newser.com
Will ImmuCell Corporation stock gain from lower inflationJuly 2025 Pullbacks & Risk Adjusted Buy/Sell Alerts - newser.com
Immucell Corp Stock (ICCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):